GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (LTS:0A9E) » Definitions » 3-Year EBITDA Growth Rate

CureVac NV (LTS:0A9E) 3-Year EBITDA Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CureVac NV 3-Year EBITDA Growth Rate?

CureVac NV's EBITDA per Share for the three months ended in Dec. 2024 was $-0.16.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of CureVac NV was -9.40% per year. The lowest was -75.60% per year. And the median was -29.30% per year.


Competitive Comparison of CureVac NV's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, CureVac NV's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CureVac NV's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where CureVac NV's 3-Year EBITDA Growth Rate falls into.


;
;

CureVac NV 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


CureVac NV  (LTS:0A9E) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


CureVac NV 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of CureVac NV's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV Business Description

Industry
Traded in Other Exchanges
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

CureVac NV Headlines

No Headlines